NCT04847544
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.
Phase: Phase 2
Role: Lead Sponsor
Start: Mar 31, 2021
Completion: Oct 15, 2021